EMA recommends Vitrakvi for EU marketing authorisation
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
List view / Grid view
The EMA has announced its approval for marketing authorisation in the EU for Vitrakvi (larotrectinib), used to treat solid tumours with a specific gene mutation.
The CMA alleges that a pharmaceutical company agreed to buy equal quantities of a pill from two drug suppliers, breaking competition law.
The pharmaceutical processing and packaging equipment market is expected to witness a high increase during the forecast period (2019-2025).
The pharmaceutical company Roche has affirmed that it was hit by a Winnti cyber-attack, thought to be supported by the Chinese government.
The FDA has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for treatment of non-Hogkin’s lymphoma and other conditions.
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.
The Senate Finance Committee has unveiled its bipartisan bill in an effort to lower drug prices, requiring drug manufacturers to justify price increases.
FDA issues warning to a company that claimed its CBD products can be used to treat cancer and Alzheimer's disease.
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
The FDA has announced that it has granted approval to the first nine generic drug applications for Pfizer’s Lyrica treatment.
Researchers have developed a model that describes how antibody solutions separate into different phases and could be used to anticipate the stability and shelf-life of drugs.
A vaccine containing the DNA of HIV is poised to enter a Phase II trial, making it the first vaccine of its kind to do so.
Orphan Drug Designation has been given to AR-501 for the treatment of lung infection in patients with cystic fibrosis.
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.
The global downstream processing market is predicted to witness record-breaking growth due to a surge in the adoption of biotech processes.